Cephalon, Lundbeck start Parkinson's Phase II/III

CEPH and H. Lundbeck (CSE:LUN) began a North American Phase II/III trial of CEP-1347 in 800 patients with early stage Parkinson's disease (PD). The double-blind, placebo-controlled, dose-finding trial...